GRM5 and depressive symptom measurement: Addex Pharmaceuticals (Geneva, Switzerland) are recently performing a Phase I clinical trials on its mGluR5 ligand ADX48621 for the treatment of depression and anxiety (ClinicalTrials.gov Identifier: NCT02447640).